CN101658494B - 一种石杉碱甲固体脂质纳米粒及其制备方法 - Google Patents
一种石杉碱甲固体脂质纳米粒及其制备方法 Download PDFInfo
- Publication number
- CN101658494B CN101658494B CN2009101925526A CN200910192552A CN101658494B CN 101658494 B CN101658494 B CN 101658494B CN 2009101925526 A CN2009101925526 A CN 2009101925526A CN 200910192552 A CN200910192552 A CN 200910192552A CN 101658494 B CN101658494 B CN 101658494B
- Authority
- CN
- China
- Prior art keywords
- huperzine
- water
- solid lipid
- oil phase
- nano particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 title claims abstract description 74
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 title claims abstract description 74
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 title claims abstract description 74
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 title claims abstract description 74
- 239000002047 solid lipid nanoparticle Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 18
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 26
- 210000003022 colostrum Anatomy 0.000 claims description 17
- 235000021277 colostrum Nutrition 0.000 claims description 17
- 239000006185 dispersion Substances 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 14
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 13
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 13
- 229920001993 poloxamer 188 Polymers 0.000 claims description 13
- 229940044519 poloxamer 188 Drugs 0.000 claims description 13
- 210000000481 breast Anatomy 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000013019 agitation Methods 0.000 claims description 8
- 238000005352 clarification Methods 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000005642 Oleic acid Substances 0.000 claims description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 4
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000002245 particle Substances 0.000 abstract description 8
- 239000003960 organic solvent Substances 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 5
- 239000003995 emulsifying agent Substances 0.000 abstract description 4
- 238000011068 loading method Methods 0.000 abstract description 4
- 210000004556 brain Anatomy 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000005538 encapsulation Methods 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 23
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003578 releasing effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000000593 microemulsion method Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000010734 process oil Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101925526A CN101658494B (zh) | 2009-09-22 | 2009-09-22 | 一种石杉碱甲固体脂质纳米粒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101925526A CN101658494B (zh) | 2009-09-22 | 2009-09-22 | 一种石杉碱甲固体脂质纳米粒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101658494A CN101658494A (zh) | 2010-03-03 |
CN101658494B true CN101658494B (zh) | 2012-05-23 |
Family
ID=41786899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101925526A Active CN101658494B (zh) | 2009-09-22 | 2009-09-22 | 一种石杉碱甲固体脂质纳米粒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101658494B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102813653B (zh) * | 2012-08-22 | 2015-12-16 | 郭涛 | 一种治疗脑缺血性痴呆的药物及其制备方法 |
CN104958267A (zh) * | 2015-06-12 | 2015-10-07 | 海南灵康制药有限公司 | 一种石杉碱甲脂微球制剂 |
CN105168182A (zh) * | 2015-10-10 | 2015-12-23 | 莆田学院附属医院 | 一种甲泼尼龙固态脂质纳米粒及其制备方法 |
CN106924172B (zh) * | 2017-03-10 | 2020-03-31 | 武汉百纳礼康生物制药有限公司 | 一种石杉碱甲溶致液晶制剂及其制备方法 |
CN109589367A (zh) * | 2018-11-22 | 2019-04-09 | 福建中医药大学 | 一种藤茶总黄酮固体脂质纳米粒及制备方法 |
CN110237037B (zh) * | 2019-07-22 | 2021-12-03 | 王盟 | 钩藤碱固体脂质纳米粒及其制备方法和冻干粉制剂 |
CN110585171A (zh) * | 2019-10-18 | 2019-12-20 | 武汉布润脑医学科技有限责任公司 | 一种替莫唑胺固体脂质纳米粒及其制备方法 |
CN112691044B (zh) * | 2019-10-22 | 2023-10-17 | 上海家化联合股份有限公司 | 正电荷修饰的固体脂质纳米粒及其制备方法 |
CN113304109A (zh) * | 2021-06-08 | 2021-08-27 | 内蒙古大唐药业股份有限公司 | 一种醋柳黄酮固体脂质纳米粒分散液及其制备方法 |
CN113786387B (zh) * | 2021-10-22 | 2022-03-08 | 中国人民解放军联勤保障部队第九八八医院 | 一种石杉碱甲脂质体及其在治疗阿尔兹海默症药物中的应用 |
CN114711288A (zh) * | 2022-03-01 | 2022-07-08 | 珠海科技学院 | 一种稳定性高的肉桂醛固体脂质纳米粒及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264058A (zh) * | 2007-03-13 | 2008-09-17 | 中国科学院上海药物研究所 | 石杉碱甲及其衍生物或其盐的缓释纳米粒、和它的制造方法 |
-
2009
- 2009-09-22 CN CN2009101925526A patent/CN101658494B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264058A (zh) * | 2007-03-13 | 2008-09-17 | 中国科学院上海药物研究所 | 石杉碱甲及其衍生物或其盐的缓释纳米粒、和它的制造方法 |
Non-Patent Citations (2)
Title |
---|
杨春荣等.离心超滤法测定石杉碱甲固体脂质纳米粒的包封率.《HEI LONG JIANG MEDICINE AND PHARMACY》.2009,第32卷(第3期),第75页第2.5栏和第1.2栏. * |
陈桐楷等.固体脂质纳米粒给药新载体的研究进展.《中国民族民间医药》.2009,第8页第2.1栏至第9页第2.6栏. * |
Also Published As
Publication number | Publication date |
---|---|
CN101658494A (zh) | 2010-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101658494B (zh) | 一种石杉碱甲固体脂质纳米粒及其制备方法 | |
Freag et al. | Stealth, biocompatible monoolein-based lyotropic liquid crystalline nanoparticles for enhanced aloe-emodin delivery to breast cancer cells: in vitro and in vivo studies | |
CN100462066C (zh) | 药剂的新制剂及其制备和应用方法 | |
CN101984958B (zh) | 纳米级阿苯达唑微粉及其制备方法 | |
CN114796111A (zh) | 一种含有难溶性药物的浓缩液以及由其制备的乳剂 | |
CN1278682C (zh) | 天然维生素e脂质纳米粒悬浮液 | |
CN113975234A (zh) | 一种羟基-α-山椒素纳米脂质体及其制备方法 | |
CN103251572B (zh) | 茶黄素肠溶微囊的制备方法及其制得的产品和应用 | |
CN110123763A (zh) | 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 | |
CN102811706A (zh) | 紫杉醇/类固醇复合物 | |
CN103405385A (zh) | 一种替莫唑胺静脉注射脂肪乳及其制备方法 | |
CN106983719A (zh) | 一种多西他赛聚合物纳米胶束注射剂、其制备方法及其在制备治疗肿瘤药物中的应用 | |
CN101658495B (zh) | 一种氢溴酸高乌甲素固体脂质纳米粒及其制备方法 | |
Sonawane et al. | Novel herbal drug delivery system: a review | |
CN103859395B (zh) | 一种高吸收率的辅酶q10的自乳化释药体系及其制备方法及应用 | |
CN105796486A (zh) | 丁苯酞脂肪乳注射剂及其制备工艺 | |
CN108498455A (zh) | 一种油性水溶药物纳米晶及其制备方法 | |
CN101884614B (zh) | 脑靶向川芎嗪口服油包油纳米乳的配制 | |
CN114681430A (zh) | 一种白藜芦醇卵磷脂纳米粒及其制备方法、用途 | |
CN113244190A (zh) | 一种胶束模板法制备的虾青素长效纳米制剂及其制法 | |
CN109481464B (zh) | 一种注射用富勒烯乳剂及其制备方法 | |
CN111494319A (zh) | 雷公藤甲素复方组合物及其制备方法与应用 | |
CN104473903B (zh) | 一种荷叶碱口服纳米给药系统及其制备方法 | |
CN114588109B (zh) | 辅酶q10乳剂及其制备方法和用途 | |
CN114632072B (zh) | 一种人参皂苷Rg5脂质纳米粒缓释制剂的制备及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160902 Address after: 510530, C2 building, No. 11, Kaiyuan Avenue, Science City, Guangzhou hi tech Industrial Development Zone, Guangdong, Sixth Patentee after: GUANGZHOU BOSITAO CONTROLLED RELEASE PHARMACEUTICAL CO., LTD. Address before: 510006 Panyu District City, Guangdong Province, University of outer ring road, No., No. 280 Patentee before: Guangdong Pharmaceutical University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211231 Address after: 510224, No. 40 Gang straight street, Bao Gang, Guangdong, Guangzhou, Haizhuqu District Patentee after: GUANGDONG PHARMACEUTICAL University Address before: 510530 6th floor, building C2, 11 Kaiyuan Avenue, Science City, Guangzhou high tech Industrial Development Zone, Guangdong Province Patentee before: GUANGZHOU BOSITAO CONTROLLED RELEASE PHARMACEUTICAL Co.,Ltd. |